Huntington's disease is a genetic neurodegenerative disorder with symptoms that are linked
to the progressive dysfunction and neuronal death in corticostriatal circuits. The causative …

Huntington’s disease (HD) is characterized by a progressive course of disease until death
15–20 years after the first symptoms occur and is caused by a mutation with expanded CAG …

… An independent data and safety monitoring board authorized each dose escalation after
unblinded review of safety data and consultation with the sponsor, Ionis Pharmaceuticals. The …

Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disorder
caused by a CAG repeat expansion in the IT‐15 gene; however, it remains unknown how …

Response inhibition is a component of executive functions, which can be divided into distinct
subprocesses by means of event-related potentials (ERPs). These subprocesses are (pre)-…

Huntington's disease (HD) is an autosomal dominantly inherited progressive neurodegenerative
disease. The exact sequel of events finally resulting in neurodegeneration is only …

… We also assessed the safety and tolerability profile of pridopidine. For our primary analysis,
all patients were eligible for inclusion in our full analysis set, in which we used the last …

Aims Selisistat, a selective SirT1 inhibitor is being developed as a potentially disease‐modifying
therapeutic for Huntington's disease ( HD ). This was the first study of selisistat in HD …

Background Huntington disease (HD) is an inherited neurodegenerative disease caused by
an abnormal expansion of a CAG repeat in the huntingtin HTT (HD) gene. The primary …

Background Previous trials have shown that pridopidine might reduce motor impairment in
patients with Huntington's disease. The aim of this study was to ascertain whether higher …